An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies

PHASE2CompletedINTERVENTIONAL
Enrollment

289

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

January 26, 2021

Study Completion Date

August 16, 2023

Conditions
Prostatic Neoplasms
Interventions
DRUG

Niraparib

Participants will receive 300 mg niraparib (3 capsules\*100 mg) orally once daily.

Trial Locations (110)

Unknown

Tucson

Los Angeles

Riverside

Sacramento

Aurora

Denver

Evanston

Danville

Louisville

New Orleans

Boston

Detroit

Omaha

New York

Durham

Lancaster

Philadelphia

Myrtle Beach

Houston

Charlottesville

Fairfax

Seattle

Madison

Camperdown

Darlinghurst

East Albury

Kurralta Park

Macquarie University

Melbourne

Murdoch

Port Macquarie

Randwick

Wahroonga

Aalst

Brussels

Charleroi

Ghent

Haine-Saint-Paul

Hasselt

Kortrijk

Liège

Namur

Ottignies

Wilrijk

Barretos

Belo Horizonte

Curitiba

Fortaleza

Ijuí

Itajaí

Joinville

Natal

Salvador

São Paulo

Vancouver

Oshawa

Toronto

Montreal

Québec

Aarhus N

Copenhagen N

Herlev

Odense C

Avignon

Besançon

Caen

Lyon

Nice

Paris

Reims

Strasbourg

Villejuif

Beersheba

Haifa

Kfar Saba

Ramat Gan

Zrifin

Alkmaar

Amsterdam

Groningen

Maastricht

Rotterdam

Moscow

Omsk

Tomsk

Seoul

Barcelona

Córdoba

Madrid

Málaga

Pozuelo de Alarcón

Santander

Santiago de Compostela

Seville

Valencia

Gothenburg

Lund

Stockholm

Umeå

Kaohsiung City

Taichung

Tainan City

Taipei

Taoyuan

Blackburn

Bristol

Cardiff

Exeter

London

Preston

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT02854436 - An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies | Biotech Hunter | Biotech Hunter